x | Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
For the Quarterly Period Ended June 30, 2013 | |
Or | |
¨ | Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
For the transition period from ________ to ___________ |
Delaware | 13-3864870 |
(State or other jurisdiction of | (IRS Employer Identification. No.) |
incorporation or organization) | |
660 Madison Avenue, Suite 1700 | 10065 |
New York, NY | (zip code) |
(Address of principal executive offices) |
Securities registered pursuant to Section 12(b) of the Act: | |
Title of each class | Name of each exchange on which registered |
common stock, $.0001 par value | Nasdaq Global Market |
Page No. | ||
June 30, 2013 | December 31, 2012 | ||||||
ASSETS | |||||||
Current assets | |||||||
Cash and cash equivalents | $ | 32,962,728 | $ | 32,017,490 | |||
Accounts receivable | 622,789 | 970,288 | |||||
Receivables from long term contract | 57,597,172 | — | |||||
Inventory | 18,452,502 | 17,641,922 | |||||
Prepaid expenses and other current assets | 930,507 | 801,149 | |||||
Deferred tax assets | 35,047,827 | 33,515,327 | |||||
Total current assets | 145,613,525 | 84,946,176 | |||||
Property, plant and equipment, net | 1,143,651 | 987,869 | |||||
Receivables from long-term contract | — | 3,771,219 | |||||
Deferred costs | 14,234,754 | 2,841,534 | |||||
Goodwill | 898,334 | 898,334 | |||||
Other assets | 2,202,294 | 2,181,720 | |||||
Deferred tax assets, net | 12,921,556 | 10,209,278 | |||||
Total assets | $ | 177,014,114 | $ | 105,836,130 | |||
LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
Current liabilities | |||||||
Accounts payable | $ | 16,258,393 | $ | 10,189,917 | |||
Accrued expenses and other current liabilities | 5,502,750 | 4,283,849 | |||||
Common stock warrants | 243,199 | 333,793 | |||||
Current portion of long term debt | 8,958,725 | 954,738 | |||||
Total current liabilities | 30,963,067 | 15,762,297 | |||||
Deferred revenue | 119,069,235 | 57,052,020 | |||||
Common stock warrants | 249,558 | 657,246 | |||||
Long term debt | 2,976,924 | 3,955,262 | |||||
Other liabilities | 348,135 | 166,303 | |||||
Total liabilities | 153,606,919 | 77,593,128 | |||||
Commitments and contingencies (Note 12) | |||||||
Stockholders’ equity | |||||||
Common stock ($.0001 par value, 100,000,000 shares authorized, 52,396,497 and 51,642,520 issued and outstanding at June 30, 2013, and December 31, 2012, respectively) | 5,240 | 5,164 | |||||
Additional paid-in capital | 170,689,389 | 167,588,374 | |||||
Accumulated deficit | (147,287,434 | ) | (139,350,536 | ) | |||
Total stockholders’ equity | 23,407,195 | 28,243,002 | |||||
Total liabilities and stockholders’ equity | $ | 177,014,114 | $ | 105,836,130 |
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
2013 | 2012 | 2013 | 2012 | |||||||||||||
Revenues | ||||||||||||||||
Research and development | $ | 964,667 | $ | 2,701,164 | $ | 2,293,031 | $ | 4,166,916 | ||||||||
Operating expenses | ||||||||||||||||
Selling, general and administrative | 3,166,149 | 3,474,691 | 6,197,499 | 5,688,568 | ||||||||||||
Research and development | 3,130,701 | 5,182,516 | 6,776,169 | 9,647,054 | ||||||||||||
Patent preparation fees | 300,581 | 376,320 | 758,736 | 712,618 | ||||||||||||
Total operating expenses | 6,597,431 | 9,033,527 | 13,732,404 | 16,048,240 | ||||||||||||
Operating loss | (5,632,764 | ) | (6,332,363 | ) | (11,439,373 | ) | (11,881,324 | ) | ||||||||
Decrease (increase) in fair value of common stock warrants | 980,289 | 904,731 | 6,090 | (94,798 | ) | |||||||||||
Interest expense | (376,323 | ) | — | (749,878 | ) | — | ||||||||||
Other income, net | 1,382 | 74 | 1,485 | 236 | ||||||||||||
Loss before income taxes | (5,027,416 | ) | (5,427,558 | ) | (12,181,676 | ) | (11,975,886 | ) | ||||||||
Benefit from (provision for) income taxes | 1,966,336 | 1,660,720 | 4,244,778 | — | 3,593,439 | |||||||||||
Net income (loss) | $ | (3,061,080 | ) | $ | (3,766,838 | ) | $ | (7,936,898 | ) | $ | (8,382,447 | ) | ||||
Earnings (loss) per share: basic and diluted | $ | (0.06 | ) | $ | (0.07 | ) | $ | (0.15 | ) | $ | (0.16 | ) | ||||
Weighted average shares outstanding: basic and diluted | 52,214,824 | 51,638,352 | 51,965,868 | 51,638,061 | ||||||||||||
Net income (loss) | $ | (3,061,080 | ) | $ | (3,766,838 | ) | $ | (7,936,898 | ) | $ | (8,382,447 | ) | ||||
Change in net unrealized gain (loss) on short-term investments | — | — | — | (4,067 | ) | |||||||||||
Comprehensive income (loss) | $ | (3,061,080 | ) | $ | (3,766,838 | ) | $ | (7,936,898 | ) | $ | (8,386,514 | ) |
Six Months Ended June 30, | |||||||
2013 | 2012 | ||||||
Cash flows from operating activities: | |||||||
Net income (loss) | $ | (7,936,898 | ) | $ | (8,382,447 | ) | |
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | |||||||
Depreciation and other amortization | 202,759 | 208,973 | |||||
Increase (decrease) in fair value of warrants | (6,090 | ) | 94,798 | ||||
Stock based compensation | 1,160,572 | 956,883 | |||||
Amortization of debt discount | 25,649 | — | |||||
Changes in assets and liabilities: | |||||||
Accounts receivable | (53,478,454 | ) | (881,827 | ) | |||
Inventory | (810,580 | ) | (8,859,970 | ) | |||
Deferred costs | (11,393,220 | ) | (1,687,599 | ) | |||
Prepaid expenses | 8,402 | (185,161 | ) | ||||
Other assets | 93,063 | 7,501 | |||||
Deferred income taxes, net | (4,244,778 | ) | (3,593,439 | ) | |||
Accounts payable, accrued expenses and other liabilities | 7,469,209 | 7,598,090 | |||||
Deferred revenue | 62,017,215 | 1,991,499 | |||||
Net cash provided by (used in) operating activities | (6,893,151 | ) | (12,732,699 | ) | |||
Cash flows from investing activities: | |||||||
Capital expenditures | (358,541 | ) | (245,189 | ) | |||
Collateral for surety bond | — | (1,347,956 | ) | ||||
Net cash provided by (used in) investing activities | (358,541 | ) | (1,593,145 | ) | |||
Cash flows from financing activities: | |||||||
Net proceeds from exercise of warrants and options | 1,375,023 | 1,690 | |||||
Payment of common stock tendered for employee tax obligations | (178,093 | ) | — | ||||
Proceeds from the issuance of debt | 7,000,000 | — | |||||
Net cash provided by (used in) financing activities | 8,196,930 | 1,690 | |||||
Net increase (decrease) in cash and cash equivalents | 945,238 | (14,324,154 | ) | ||||
Cash and cash equivalents at beginning of period | 32,017,490 | 49,256,930 | |||||
Cash and cash equivalents at end of period | $ | 32,962,728 | $ | 34,932,776 | |||
Supplemental disclosure of non-cash financing activities: | |||||||
Reclass of common stock warrant liability to additional paid-in capital upon warrant exercise | $ | 492,191 | $ | — | |||
Remaining grant-date fair value of warrants recorded as other assets | $ | 251,397 | $ | — |
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
2013 | 2012 (Revised) | 2013 | 2012 (Revised) | ||||||||||||
Net income (loss) for basic and diluted EPS | $ | (3,061,080 | ) | $ | (3,766,838 | ) | $ | (7,936,898 | ) | $ | (8,382,447 | ) | |||
Weighted-average shares for basic and diluted | 52,214,824 | 51,638,352 | 51,965,868 | 51,638,061 | |||||||||||
Earnings (loss) per share for basic and diluted | $ | (0.06 | ) | $ | (0.07 | ) | $ | (0.15 | ) | $ | (0.16 | ) |
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||
2013 | 2012 | 2013 | 2012 | ||||||||
Stock Options | 2,799,122 | 2,830,810 | 2,809,465 | 2,815,345 | |||||||
Stock-Settled Stock Appreciation Rights | 447,156 | 461,462 | 449,423 | 377,913 | |||||||
Restricted Stock Units | 977,409 | 372,637 | 990,240 | 240,824 | |||||||
Warrants | 1,875,743 | 2,253,902 | 2,034,477 | 2,273,281 |
• | Level 1 – Quoted prices for identical instruments in active markets. |
• | Level 2 – Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations where inputs are observable or where significant value drivers are observable. |
• | Level 3 – Instruments where significant value drivers are unobservable to third parties. |
June 30, 2013 | December 31, 2012 (Revised) | ||||||
Common stock warrants, current | $ | 243,199 | $ | 333,793 | |||
Common stock warrants, non-current | 249,558 | 657,246 | |||||
$ | 492,757 | $ | 991,039 |
June 30, 2013 | December 31, 2012 | ||||||
Laboratory equipment | $ | 2,388,086 | $ | 2,305,410 | |||
Leasehold improvements | 2,887,415 | 2,817,123 | |||||
Computer equipment | 540,890 | 458,421 | |||||
Furniture and fixtures | 468,391 | 345,287 | |||||
6,284,782 | 5,926,241 | ||||||
Less - accumulated depreciation | (5,141,131 | ) | (4,938,372 | ) | |||
Property, plant and equipment, net | $ | 1,143,651 | $ | 987,869 |
June 30, 2013 | December 31, 2012 | ||||||
Loss contingency | $ | 2,561,374 | $ | 2,491,981 | |||
Bonus | 803,590 | 250,000 | |||||
Professional fees | 560,156 | 579,609 | |||||
Vacation | 363,565 | 328,463 | |||||
Other | 1,214,065 | 633,796 | |||||
Accrued expenses and other current liabilities | $ | 5,502,750 | $ | 4,283,849 |
December 31, 2012 | |||||||||||
As Originally Reported | Adjustments | Revised | |||||||||
ASSETS | |||||||||||
Current assets | |||||||||||
Cash and cash equivalents | $ | 32,017,490 | $ | 32,017,490 | |||||||
Accounts receivable | 970,288 | 970,288 | |||||||||
Inventory | 17,641,922 | 17,641,922 | |||||||||
Prepaid expenses and other current assets | 801,149 | 801,149 | |||||||||
Deferred tax assets, net | 33,515,327 | 33,515,327 | |||||||||
Total current assets | 84,946,176 | 84,946,176 | |||||||||
Property, plant and equipment, net | 987,869 | 987,869 | |||||||||
Receivables from long-term contract | 3,771,219 | 3,771,219 | |||||||||
Deferred costs | 2,841,534 | 2,841,534 | |||||||||
Goodwill | 898,334 | 898,334 | |||||||||
Other assets | 2,181,720 | 2,181,720 | |||||||||
Deferred tax assets, net | 10,209,278 | 10,209,278 | |||||||||
Total assets | $ | 105,836,130 | $ | — | $ | 105,836,130 | |||||
LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||
Current liabilities | |||||||||||
Accounts payable | $ | 10,189,917 | $ | 10,189,917 | |||||||
Accrued expenses and other current liabilities | 4,283,849 | 4,283,849 | |||||||||
Current common stock warrants | 287,036 | 46,757 | 333,793 | ||||||||
Current portion of long term debt | 954,738 | 954,738 | |||||||||
Total current liabilities | 15,715,540 | 46,757 | 15,762,297 | ||||||||
Deferred revenue | 57,052,020 | 57,052,020 | |||||||||
Common stock warrants | — | 657,246 | 657,246 | ||||||||
Long term debt | 3,955,262 | 3,955,262 | |||||||||
Other liabilities | 166,303 | 166,303 | |||||||||
Total liabilities | 76,889,125 | 704,003 | 77,593,128 | ||||||||
Stockholders’ equity | |||||||||||
Common stock | 5,164 | 5,164 | |||||||||
Additional paid-in capital | 152,340,303 | 15,248,071 | 167,588,374 | ||||||||
Accumulated deficit | (123,398,462 | ) | (15,952,074 | ) | (139,350,536 | ) | |||||
Total stockholders’ equity | 28,947,005 | (704,003 | ) | 28,243,002 | |||||||
Total liabilities and stockholders’ equity | $ | 105,836,130 | $ | — | $ | 105,836,130 |
Three Months Ended June 30, 2012 | |||||||||||
As Originally Reported | Adjustments | Revised | |||||||||
Revenues | |||||||||||
Research and development | $ | 2,701,164 | $ | 2,701,164 | |||||||
Operating expenses | |||||||||||
Selling, general and administrative | 3,474,691 | 3,474,691 | |||||||||
Research and development | 5,182,516 | 5,182,516 | |||||||||
Patent preparation fees | 376,320 | 376,320 | |||||||||
Total operating expenses | 9,033,527 | — | 9,033,527 | ||||||||
Operating loss | (6,332,363 | ) | — | (6,332,363 | ) | ||||||
Decrease (increase) in fair value of common stock warrants | 325,012 | 579,719 | 904,731 | ||||||||
Other income, net | 74 | 74 | |||||||||
Loss before benefit from income taxes | (6,007,277 | ) | 579,719 | (5,427,558 | ) | ||||||
Benefit from income taxes | 1,660,720 | 1,660,720 | |||||||||
Net income (loss) | $ | (4,346,557 | ) | $ | 579,719 | $ | (3,766,838 | ) | |||
Basic and diluted earnings (loss) per share | $ | (0.08 | ) | $ | 0.01 | $ | (0.07 | ) | |||
Weighted average shares outstanding: basic and diluted | 51,638,352 | — | 51,638,352 |
Six Months Ended June 30, 2012 | |||||||||||
As Originally Reported | Adjustments | Revised | |||||||||
Revenues | |||||||||||
Research and development | $ | 4,166,916 | $ | 4,166,916 | |||||||
Operating expenses | |||||||||||
Selling, general and administrative | 5,688,568 | 5,688,568 | |||||||||
Research and development | 9,647,054 | 9,647,054 | |||||||||
Patent preparation fees | 712,618 | 712,618 | |||||||||
Total operating expenses | 16,048,240 | — | 16,048,240 | ||||||||
Operating loss | (11,881,324 | ) | — | (11,881,324 | ) | ||||||
Decrease (increase) in fair value of common stock warrants | (111,801 | ) | 17,003 | (94,798 | ) | ||||||
Interest expense | — | — | |||||||||
Other income, net | 236 | 236 | |||||||||
Loss before benefit from income taxes | (11,992,889 | ) | 17,003 | (11,975,886 | ) | ||||||
Benefit from income taxes | 3,593,439 | 3,593,439 | |||||||||
Net income (loss) | $ | (8,399,450 | ) | $ | 17,003 | $ | (8,382,447 | ) | |||
Basic and diluted earnings (loss) per share | $ | (0.16 | ) | $ | — | $ | (0.16 | ) | |||
Weighted average shares outstanding: basic and diluted | 51,638,061 | — | 51,638,061 |
31.1 | Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
31.2 | Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
32.1 | Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
32.2 | Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
101.INS | XBRL Instance Document |
101.SCH | XBRL Taxonomy Extension Schema |
101.CAL | XBRL Taxonomy Extension Calculation Linkbase |
101.DEF | XBRL Taxonomy Extension Definition Linkbase |
101.LAB | XBRL Taxonomy Extension Label Linkbase |
101.PRE | XBRL Taxonomy Extension Presentation Linkbase |
SIGA TECHNOLOGIES, INC. | ||||
(Registrant) | ||||
Date: | August 5, 2013 | By: | /s/ Daniel J. Luckshire | |
Daniel J. Luckshire | ||||
Executive Vice President and | ||||
Chief Financial Officer | ||||
(Principal Financial Officer and | ||||
Principal Accounting Officer) |
1. | I have reviewed this quarterly report on Form 10-Q of SIGA Technologies, Inc.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
(a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
(b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
(c) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
(d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
(a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
(b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Date: August 5, 2013 |
/s/ Eric A. Rose |
Eric A. Rose, M.D. |
Chairman and Chief Executive Officer |
1. | I have reviewed this quarterly report on Form 10-Q of SIGA Technologies, Inc.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
(a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
(b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
(c) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
(d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
(a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
(b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Date: August 5, 2013 |
/s/ Daniel J. Luckshire |
Daniel J. Luckshire |
Executive Vice President and Chief Financial Officer |
(1) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
/s/ Eric A. Rose |
Eric A. Rose, M.D. |
Chairman and Chief Executive Officer |
August 5, 2013 |
(1) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
/s/ Daniel J. Luckshire |
Daniel J. Luckshire |
Executive Vice President and Chief Financial Officer |
August 5, 2013 |
Legal Proceedings
|
6 Months Ended |
---|---|
Jun. 30, 2013
|
|
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Legal Proceedings In December 2006, PharmAthene, Inc. (“PharmAthene”) filed an action against SIGA in the Delaware Court of Chancery (the “Court” or “Court of Chancery”) captioned PharmAthene, Inc. v. SIGA Technologies, Inc., C.A. No. 2627-N. In its amended complaint, PharmAthene asked the Court to order the Company to enter into a license agreement with PharmAthene with respect to ST-246, now also known as Arestvyr, to declare that the Company is obliged to execute such a license agreement, and to award damages resulting from the Company’s supposed breach of that obligation. PharmAthene also alleged that the Company breached an obligation to negotiate such a license agreement in good faith, and sought damages for promissory estoppel and unjust enrichment based on supposed information, capital, and assistance that PharmAthene allegedly provided to the Company during the negotiation process. The Court tried the case in January 2011. In September 2011, the Court issued its post-trial opinion. The Court denied PharmAthene’s requests for specific performance and expectation damages measured by the present value of estimated future profits. Nevertheless, the Court held that the Company breached its duty to negotiate in good faith and was liable under the doctrine of promissory estoppel. The Court consequently awarded to PharmAthene what the Court described as an equitable payment stream or equitable lien consisting of fifty percent of the net profits that the Company achieves from sales of ST-246 after the Company secures $40 million in net profits, for ten years following the first commercial sale. In addition, the Court awarded PharmAthene one-third of its reasonable attorneys’ fees and expert witness expenses. In May 2012, the Court entered its final order and judgment in this matter, implementing its post-trial opinion. Among other things, the final order and judgment provided that (a) net profits would be calculated in accordance with generally accepted accounting principles applied consistently with how they are applied in the preparation of the Company’s financial statements, (b) the net profits calculation would take into account expenses relating to ST-246 commencing with the Company’s acquisition of ST-246 in August 2004, and (c) PharmAthene could recover $2.4 million of attorneys’ fees and expenses. As of June 30, 2013, SIGA has recorded a $2.6 million loss contingency with respect to the fee, expense and interest portion of the judgment. In June 2012, the Company appealed to the Supreme Court of the State of Delaware the final order and judgment and certain earlier rulings of the Court of Chancery. Shortly thereafter, PharmAthene filed its cross-appeal. The Company obtained a stay of enforcement of the fee and expense portion of the judgment by filing a surety bond for the amount of the judgment plus post-judgment interest. The Company posted $1.3 million as collateral for the surety bond which is recorded in other assets as of June 30, 2013. The parties briefed the issues, and argued before the Delaware Supreme Court, en banc, on January 10, 2013. On May 24, 2013, the Supreme Court of Delaware issued its decision, affirming the Delaware Court of Chancery’s judgment in part, reversing it in part, and remanding to Vice Chancellor Parsons. The Supreme Court affirmed the Chancery Court determination that the Company had breached its contractual obligation to negotiate in good faith; reversed the promissory estoppel holding; and, reversed the Vice Chancellor’s equitable damages award. The Supreme Court held that the trial judge may award expectation damages for breach of the contractual duty to negotiate in good faith if such damages are proven with reasonable certainty, and remanded to the Chancery Court for consideration of damages consistent with that holding. The Supreme Court also reversed the Chancery Court’s award of attorney fees and expert witness fees because they were predicated in part on a now-reversed finding of liability on PharmAthene’s promissory estoppel claim. The Supreme Court held that the Chancery Court could reevaluate on remand an alternative award, if any, of attorneys’ fees and expert testimony expenses consistent with the Supreme Court’s opinion. Finally, the Supreme Court declined to consider all claims raised in PharmAthene’s cross appeal because it affirmed the Chancery Court’s finding that the Company was liable for breaching its contractual obligation to negotiate in good faith. On June 11, 2013, the Supreme Court issued its mandate to the Court of Chancery with the decision described above. On June 26, 2013, the parties appeared before Vice Chancellor Parsons to discuss the remand, at which time PharmAthene declared its desire to supplement the record with further evidence. Following briefing, the parties expect the Chancery Court to hear argument on this PharmAthene motion in August. After the Chancery Court determines the scope of the record, we expect the Chancery Court to require further briefing by the parties on the remedy to be awarded. No assurances can be given as to the Chancery Court’s determinations on remand. From time to time, the Company is involved in disputes or legal proceedings arising in the ordinary course of business. The Company believes that there is no dispute or litigation pending, except as discussed above, that could have, individually or in the aggregate, a material adverse effect on its financial position, results of operations or cash flows. |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME/LOSS (Unaudited) (USD $)
|
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jun. 30, 2013
|
Jun. 30, 2012
|
Jun. 30, 2013
|
Jun. 30, 2012
|
|
Revenues | ||||
Research and development | $ 964,667 | $ 2,701,164 | $ 2,293,031 | $ 4,166,916 |
Operating expenses | ||||
Selling, general and administrative | 3,166,149 | 3,474,691 | 6,197,499 | 5,688,568 |
Research and development | 3,130,701 | 5,182,516 | 6,776,169 | 9,647,054 |
Patent preparation fees | 300,581 | 376,320 | 758,736 | 712,618 |
Total operating expenses | 6,597,431 | 9,033,527 | 13,732,404 | 16,048,240 |
Operating loss | (5,632,764) | (6,332,363) | (11,439,373) | (11,881,324) |
Decrease (increase) in fair value of common stock warrants | 980,289 | 904,731 | 6,090 | (94,798) |
Interest expense | 376,323 | 0 | 749,878 | 0 |
Other income, net | 1,382 | 74 | 1,485 | 236 |
Loss before income taxes | (5,027,416) | (5,427,558) | (12,181,676) | (11,975,886) |
Benefit from income taxes | 1,966,336 | 1,660,720 | 4,244,778 | 3,593,439 |
Net income (loss) | (3,061,080) | (3,766,838) | (7,936,898) | (8,382,447) |
Earnings Per Share, Basic and Diluted | $ (0.06) | $ (0.07) | $ (0.15) | $ (0.16) |
Weighted Average Number of Shares Outstanding, Basic and Diluted | 52,214,824 | 51,638,352 | 51,965,868 | 51,638,061 |
Comprehensive income (loss) | ||||
Change in net unrealized gain (loss) on short-term investments | 0 | 0 | 0 | (4,067) |
Comprehensive income (loss) | $ (3,061,080) | $ (3,766,838) | $ (7,936,898) | $ (8,386,514) |
Fair Value Measurements (Notes)
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2013
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures | The carrying value of cash and cash equivalents, accounts payable and accrued expenses approximates fair value due to the relatively short maturity of these instruments. Common stock warrants which are classified as liabilities are recorded at their fair market value as of each reporting period. The measurement of fair value requires the use of techniques based on observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our market assumptions. The inputs create the following fair value hierarchy:
The Company uses model-derived valuations where inputs are observable in active markets to determine the fair value of certain common stock warrants on a recurring basis and classify such warrants in Level 2. The Company utilizes the Black-Scholes model consisting of the following variables: (i) the closing price of SIGA’s common stock; (ii) the expected remaining life of the warrant; (iii) the expected volatility using a weighted-average of historical volatilities from a combination of SIGA and comparable companies; and (iv) the risk-free market rate. At June 30, 2013 and December 31, 2012, the fair value of liability classified warrants were as follows:
At June 30, 2013 and December 31, 2012, the Company also had $12.0 million and $5 million in outstanding debt, respectively. The fair value of this debt is a Level 2 measurement. The fair value of the loan approximates carrying value at June 30, 2013. For the three and six months ended June 30, 2013 and 2012, SIGA did not hold any Level 3 securities. |
Revision of Consolidated Financial Statements (Notes)
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2013
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Revision of Consolidated Financial Statements [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounting Changes and Error Corrections | 13. Revision of Consolidated Financial Statements Subsequent to the issuance of its annual report on Form 10-K for the year ended December 31, 2012 as filed on March 6, 2013, the Company determined certain outstanding warrants to purchase common stock of the Company (the “Warrants”) should have been recorded as liabilities rather than equity and that non-cash charges resulting from required periodic “mark-to-market” adjustments of the Warrants also should have been recorded. For the year ended December 31, 2012 and the quarters therein, the quantitative and qualitative impact of the non-cash adjustments on net loss were not material and consequently, the Company revised prior period amounts as disclosed within the Form 10-K/A filed on May 14, 2013. As these are non-cash items, there is no impact to net cash used in operations for the three and six months ended June 30, 2012. The effects of the revision on the unaudited financial statements are summarized below:
|
Fair Value Measurements (Details) (USD $)
|
Jun. 30, 2013
|
Dec. 31, 2012
|
---|---|---|
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Common stock warrants, current | $ 243,199 | $ 333,793 |
Common stock warrants, noncurrent | 249,558 | 657,246 |
Term loan | 12,000,000 | 5,000,000 |
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
|
||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Common stock warrants, current | 333,793 | |
Common stock warrants, noncurrent | 657,246 | |
Common stock warrants, current and noncurrent | $ 492,757 | $ 991,039 |
Accrued Expenses and Other Current Liabilities (Details) (USD $)
|
Jun. 30, 2013
|
Dec. 31, 2012
|
---|---|---|
Payables and Accruals [Abstract] | ||
Loss contingency | $ 2,561,374 | $ 2,491,981 |
Bonus | 803,590 | 250,000 |
Professional fees | 560,156 | 579,609 |
Vacation | 363,565 | 328,463 |
Other | 1,214,065 | 633,796 |
Total | $ 5,502,750 | $ 4,283,849 |
Equity and Financial Instruments (Details) (USD $)
|
3 Months Ended | 6 Months Ended | 0 Months Ended | 12 Months Ended | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2013
|
Jun. 30, 2012
|
Jun. 30, 2013
|
Jun. 30, 2012
|
Apr. 29, 2013
|
Mar. 31, 2013
|
Dec. 31, 2012
|
Dec. 31, 2006
|
Apr. 30, 2013
Affiliated Entity
|
Jun. 18, 2010
Affiliated Entity
|
Dec. 31, 2009
Affiliated Entity
|
Jun. 19, 2008
Affiliated Entity
|
Jun. 19, 2008
Extended Expiration Period [Member]
Affiliated Entity
|
Jun. 30, 2013
Fair Value, Measurements, Recurring [Member]
Fair Value, Inputs, Level 2 [Member]
|
Dec. 31, 2012
Fair Value, Measurements, Recurring [Member]
Fair Value, Inputs, Level 2 [Member]
|
|
Equity [Abstract] | |||||||||||||||
Capital units, authorized | 110,000,000 | 110,000,000 | |||||||||||||
Common stock, shares authorized | 100,000,000 | 100,000,000 | 100,000,000 | ||||||||||||
Preferred stock, shares authorized | 10,000,000 | 10,000,000 | |||||||||||||
Class of Warrant or Right [Line Items] | |||||||||||||||
Common stock warrants, current and noncurrent | $ 492,757 | $ 991,039 | |||||||||||||
Change In fair value of common stock warrants | (980,289) | (904,731) | (6,090) | 94,798 | |||||||||||
Commitment to Invest | 8,000,000 | ||||||||||||||
Warrants to purchase percentage of acquired shares | 40.00% | ||||||||||||||
Warrants to purchase common stock | 1,000,000 | 250,000 | 718,954 | 326,797 | 238,000 | ||||||||||
Exercise price of warrants to purchase common stock | 2.92 | 2.92 | 4.99 | 3.29 | 3.519 | 3.519 | 3.06 | ||||||||
Warrants expired | 202,451 | ||||||||||||||
Common stock, shares issued | 52,396,497 | 52,396,497 | 51,642,520 | 1,797,386 | 816,993 | ||||||||||
Proceeds from issuance of warrants and options | $ 5,500,000 | $ 2,500,000 | |||||||||||||
Service agreement term | 3 years | ||||||||||||||
Warrants contractual term (in years) | 2 years | 4 years | 4 years | ||||||||||||
Warrants exercised | 407,784 | ||||||||||||||
Warrants, outstanding | 407,784 | 407,784 | 815,568 |
Interim Condensed Consolidated Financial Statements
|
6 Months Ended |
---|---|
Jun. 30, 2013
|
|
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Interim Condensed Consolidated Financial Statements | Condensed Consolidated Financial Statements The financial statements are presented in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (the “SEC”) for quarterly reports on Form 10-Q and should be read in conjunction with the Company’s audited financial statements and notes thereto for the year ended December 31, 2012, included in the 2012 Annual Report on Form 10-K/A. All terms used but not defined elsewhere herein have the meaning ascribed to them in the Company’s 2012 Annual Report on Form 10-K/A filed on May 14, 2013. In the opinion of management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results of the interim periods presented have been included. The 2012 year-end balance sheet data was derived from the audited financial statements but does not include all disclosures required by U.S. GAAP. The results of operations for the three and six months ended June 30, 2013 are not necessarily indicative of the results expected for the full year. The financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. As of July 31, 2013, the Company has delivered an aggregate of approximately 590,000 courses of Arestvyr™ (tecovirimat), also known as ST-246®, to the U.S. Strategic National Stockpile (the “Strategic Stockpile”). As a result, SIGA has met a key requirement of its procurement contract with the Biomedical Advanced Research and Development Authority (“BARDA”) (refer to Note 2) and expects to receive payment of approximately $79 million in the third quarter of 2013 for the courses of product delivered to date. Management believes that the funds expected to be generated from its procurement contract, together with existing capital resources and continuing government grants and contracts, will be sufficient to support its operations beyond the next twelve months. |
Equity and Financial Instruments (Notes)
|
6 Months Ended |
---|---|
Jun. 30, 2013
|
|
Equity [Abstract] | |
Equity and Financial Instruments | Equity and Financial Instruments On June 30, 2013, the Company’s authorized share capital consisted of 110,000,000 shares, of which 100,000,000 are designated common shares and 10,000,000 are designated preferred shares. The Company’s Board of Directors is authorized to issue preferred shares in series with rights, privileges and qualifications of each series determined by the Board. At June 30, 2013 and December 31, 2012, the fair market value of outstanding warrants recorded as liabilities was $492,757 and $991,039 (revised), respectively. The Company applied the Black-Scholes model to calculate the fair values of the respective derivative instruments using the contractual term of the warrants. Management estimates the expected volatility using a combination of the Company’s historical volatility and the volatility of a group of comparable companies. For the three months ended June 30, 2013 and June 30, 2012, the Company recorded gains of $980,289 and $904,731 (revised), respectively, as a result of net decreases in fair value for warrants outstanding during the respective periods. On April 30, 2013, SIGA entered into a Services Agreement with M&F for certain professional and administrative services. The Services Agreement has a term of three years. As consideration for the Services Agreement, SIGA issued warrants to M&F to acquire 250,000 shares of common stock at an exercise price of $3.29 per share. The warrants are fully vested, immediately exercisable and remain exercisable for two years from issuance. As the warrants are immediately exercisable, the grant-date fair value, determined using the Black-Scholes model as previously described, is recorded as an asset with a corresponding increase to equity. The asset is amortized over the contractual term of the warrant. 2008 Financing On June 19, 2008, SIGA entered into a letter agreement (as amended, the “Letter Agreement”) that expired on June 19, 2010, with MacAndrews & Forbes LLC (“M&F”), a related party, for M&F’s commitment to invest, at SIGA’s discretion or at M&F’s option, up to $8 million in exchange for (i) SIGA common stock and (ii) warrants to purchase 40% of the number of SIGA shares acquired by M&F. In consideration for the commitment of M&F reflected in the Letter Agreement, on June 19, 2008, M&F received warrants to purchase 238,000 shares of SIGA common stock, initially exercisable at $3.06 (the “Commitment Warrants”). The Commitment Warrants were subject to anti-dilution adjustments and exercisable until June 19, 2012. On June 19, 2012, the Commitment Warrants were amended to extend expiration to June 19, 2014. Due to certain anti-dilution provisions, the Commitment Warrants are recorded as a liability, and consequently the “mark-to-market” adjustment to the fair value from the extended term was accounted for immediately upon modification. In 2009, SIGA issued to M&F 816,993 shares of common stock and 326,797 warrants to acquire common stock in exchange for total proceeds of $2.5 million. The warrants are exercisable for a term of four years from issuance and had an exercise price of $3.519 per share, prior to anti-dilution adjustments. On April 29, 2013, 202,451 of the aforementioned warrants issued in 2009 expired. On June 18, 2010, M&F notified SIGA of its intention to exercise its right to invest $5.5 million, the remaining amount available under the Letter Agreement following earlier investments and entered into a Deferred Closing and Registration Rights Agreement dated as of June 18, 2010 with the Company. On July 26, 2010, upon satisfaction of certain customary closing conditions, including the expiration of the applicable waiting period pursuant to the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, M&F funded the $5.5 million purchase price to SIGA in exchange for the issuance of (i) 1,797,386 shares of common stock and (ii) warrants to purchase 718,954 shares of SIGA common stock at an exercise price of $3.519 per share; the warrants are exercisable for a term of four years from issuance. The number of shares issuable pursuant to the warrants granted under the Letter Agreement, as well as the exercise price of those warrants, may be subject to adjustment as a result of the effect of future equity issuances on certain anti-dilution provisions in the related warrant agreements. 2006 Placements In 2006, the Company issued 1,000,000 warrants with an initial exercise price of $4.99 per share (the “2006 Warrants”). The 2006 Warrants may be exercised through and including October 19, 2013. At June 30, 2013 and December 31, 2012, 407,784 and 815,568, respectively, of the 2006 Warrants at an exercise price of $2.92 were outstanding. In March 2013, 407,784 of the 2006 Warrants were exercised. The number of shares issuable pursuant to the Warrants may be subject to further adjustment as a result of the effect of future equity issuances on anti-dilution provisions in the related warrant agreements. |
Related Party Transactions
|
6 Months Ended |
---|---|
Jun. 30, 2013
|
|
Related Party Transactions [Abstract] | |
Related Party Transactions | Related Party Transactions On December 1, 2009, the Company entered into an Office Services Agreement with an affiliate of M&F to occupy office space for approximately $8,000 per month. An amendment in February 2012 increased the monthly payment to $12,000 to appropriately reflect expanded use of space. The Office Services Agreement was canceled effective March 31, 2013. In October 2012, the Company funded a letter of credit and deposit to take advantage of a lease for office space secured by an affiliate of M&F from a third party landlord on behalf of the Company. Pursuant to such letter of credit, in January 2013 the Company entered into a sublease in which the Company will pay all costs associated with the lease, including rent. All payments made by the Company pursuant to the sublease will either be directly or indirectly made to the third-party landlord and not retained by M&F or any affiliate. The new sublease replaced the Office Services Agreement that is described in the previous paragraph, and occupancy commenced on April 1, 2013. The sublease allows for a free rent period of five months beginning April 1, 2013; subsequent to the free rent period, monthly rent payments are scheduled to be $60,000 for the first five years and $63,000 for the next two years. Rent payments under the lease and sublease are subject to customary rent escalation clauses. In April 2013, the Company entered into a Services Agreement with M&F and a warrant agreement with M&F (refer to Note 3). A member of the Company’s Board of Directors is a member of the Company’s outside counsel. During the six months ended June 30, 2013 and 2012, the Company incurred costs of $789,000 and $875,000, respectively, related to services provided by the outside counsel. On June 30, 2013, the Company’s outstanding payables included $256,000 payable to the outside counsel. |
Per Share Data (Notes)
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2013
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Per Share Data | Per Share Data The objective of basic earnings per share (“EPS”) is to measure the performance of an entity over the reporting period by dividing income (loss) by the weighted average shares outstanding. The objective of diluted EPS is consistent with that of basic EPS, except that it also gives effect to all potentially dilutive common shares outstanding during the period. The following is a reconciliation of the basic and diluted net income (loss) per share computation:
The Company incurred losses for the three and six months ended June 30, 2013 and 2012 and as a result, certain equity instruments are excluded from the calculation of diluted earnings (loss) per share as the effect of such shares is anti-dilutive. The weighted average number of equity instruments excluded consist of:
The appreciation of each stock-settled stock appreciation right was capped at a determined maximum value. As a result, the weighted average number shown in the table above for stock-settled stock appreciation rights reflects the weighted average maximum number of shares that could be issued. |
Related Party Transactions (Details) (USD $)
|
6 Months Ended | 6 Months Ended | |||
---|---|---|---|---|---|
Jun. 30, 2013
Affiliated Entity
|
Feb. 29, 2012
Affiliated Entity
|
Dec. 01, 2009
Affiliated Entity
|
Jun. 30, 2013
Member of Board of Directors
|
Jun. 30, 2012
Member of Board of Directors
|
|
Related Party Transaction [Line Items] | |||||
Lease property price per month | $ 12,000 | $ 8,000 | |||
Free rent period | 5 months | ||||
Monthly rental payments first five years | 60,000 | ||||
Initial rent period | 5 years | ||||
Monthly rental payments after five years | 63,000 | ||||
Rent period after first five years | 2 years | ||||
Legal fees | 789,000 | 875,000 | |||
Accounts payable to related party | $ 256,000 |
Income Taxes (Details) (USD $)
|
3 Months Ended | 6 Months Ended | |||
---|---|---|---|---|---|
Jun. 30, 2013
|
Jun. 30, 2012
|
Jun. 30, 2013
|
Jun. 30, 2012
|
Dec. 31, 2012
|
|
Income Tax Disclosure [Abstract] | |||||
Deferred Tax Assets, Net of Valuation Allowance | $ 48,000,000 | $ 48,000,000 | $ 43,700,000 | ||
Deferred Tax Assets, Valuation Allowance | 4,300,000 | 4,300,000 | 4,300,000 | ||
Benefit from income taxes | $ 1,966,336 | $ 1,660,720 | $ 4,244,778 | $ 3,593,439 |